Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
You may also be interested in...
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Positive new top-line Phase III results look set to strengthen Opdivo combination therapy in first-line kidney cancer through an improved toxicity profile.
Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.